⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791300 | 0.72 | — | — | |
| SCHEMBL589073 | 0.70 | — | — | |
| SCHEMBL11922777 | 0.70 | — | — | |
| SCHEMBL11316991 | 0.70 | — | — | |
| SCHEMBL21093432 | 0.70 | — | — | |
| SCHEMBL11990342 | 0.69 | IDH1 (0.40) | — | |
| SCHEMBL12483070 | 0.68 | ALDH1A1 (0.46) | — | |
| SCHEMBL17821042 | 0.67 | TRIM24 (0.50) | — | |
| SCHEMBL2625521 | 0.67 | CA9 (0.38) | — | |
| SCHEMBL16093372 | 0.67 | CA12 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102285914-A | Synthesis method of 2-(1-methyl-6-carboxy-1,6-dihydropyridine)-acetic acid | — | 2011-12-21 | — | — | CN | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024217500-A1 | ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-118772110-A | Heteroarone compounds and their use as LSD1 inhibitors | 上海复星医药（集团）股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20220213093-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
| US-11028066-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-6221870-B1 | TREATMENT OF DEPRESSION, ANXIETY, BIPOLAR DISORDERS AND ADHD | NOVARTIS AG (CH) | 2001-04-24 | — | — | US | disclosed |
| US-5955615-A | COUPLERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| EP-0767220-B1 | Pyridonmethidazo dyes | BAYER AG (DE) | 1999-04-28 | — | — | EP | disclosed |
| US-5808015-A | RED FIBER REACTIVE, ACID DYES FOR CELLULOSE FIBERS, COTTON, WOOL, SILK, POLYAMIDES, POLYESTERS, POLYOLEFINS AND POLYACRYLONITRILE; COLORFASTNESS; BRIGHTNESS; TRIAZINE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-09-15 | — | — | US | disclosed |
| EP-0767220-A1 | Pyridonmethidazo dyes | BAYER AG (DE) | 1997-04-09 | — | — | EP | disclosed |